Reference : Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Scientific journals : Article
Human health sciences : Rheumatology
Human health sciences : Gastroenterology & hepatology
Human health sciences : Pharmacy, pharmacology & toxicology
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Franchimont, N. [> > > >]
Putzeys, V. [> > > >]
Collette, Julien [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
Vermeire, S. [> > > >]
Rutgeerts, P. [> > > >]
De Vos, M. [> > > >]
Van Gossum, A. [> > > >]
Franchimont, D. [> > > >]
Fiasse, R. [> > > >]
Pelckmans, P. [> > > >]
Malaise, Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie >]
Belaiche, Jacques mailto [Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie]
Louis, Edouard mailto [Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie >]
Alimentary Pharmacology & Therapeutics
Blackwell Publishing Ltd
Yes (verified by ORBi)
[en] BACKGROUND: Crohn's disease is associated with low bone mineral density and altered bone metabolism. AIM: To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab. METHODS: We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group. RESULTS: Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14-51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30-61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter. CONCLUSION: Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Restricted access
Rapid improvement of bone metabolism... 2004.pdfPublisher postprint3.44 MBRequest copy
Open access
Rapid improvement of bone metabolism...- Aliment Pharmacol Ther 2004 20 607-614.pdfAuthor postprint210.82 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.